IPHA says Ireland must "get serious" about R&D
The Irish Pharmaceutical Healthcare Association has issued a call for the government to "get serious" about clinical research. Ireland has a unique opportunity to now position itself as the hub for translation research that would open the door of the country's excellent research capabilities to more R&D collaboration, a meeting of the Irish Platform for Patients' Organization, Science and Industry (IPPOSI) in Dublin heard last month.
The IPHA's chief executive, Anne Nolan, told the over 250 delegates that, "if Ireland is serious about attracting a worthwhile program of clinical trials and world class researchers to the country, we need to make innovation work for patients."
IPPOSI chairman Michael Griffin said: "it is vital for patients that the latest, most advanced medicines and technologies are available. We know that patients want access to the latest medicines and treatments and are interested in being involved in clinical research."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze